16 / 19
Notes:
Page 37
Volume 09
Journal of Alzheimers Disease & Parkinsonism
ISSN: 2161-0460
Epilepsy 2019
Parkinsons Congress 2019
August 29-31, 2019
JOINT EVENT
conferenceseries
.com
August 29-31, 2019 Vienna, Austria
&
5
th
International Conference on
Epilepsy & Treatment
5
th
World Congress on
Parkinsons & Huntington Disease
NeuroEPO in parkinson’s disease
Ivonne Pedroso Ibañez
International Center for Neurological Restoration, Cuba
Introduction:
Strategies to treat patients with Parkinson’s disease cannot stop the progression. In Cuba, the Center
for Molecular Immunology is a cutting edge scientific center where recombinant human erythropoietins with low
sialic acid (NeuroEPO) are produced. We are looking for different alternatives that modify the natural course of the
disease and recent research has demonstrated the neuroprotective properties of erythropoietin.
Objective:
Assess safety and the positive results of the cognitive tests of recombinant human erythropoietin with low
sialic acid in a group of Parkinson’s disease patients.
Methods:
The study was conducted in PD patients from the outpatient clinic of CIREN, including n = 26 patients
between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The study employed an intranasal
formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to
evaluate global cognitive functioning, executive function, and memory. Safety was evaluated by recording adverse
events (by intensity and causality). Hematological parameters and blood pressure were also measured because of
their direct relationship to the medication’s action.
Results:
Five patients experienced mild adverse events with a possible causal relationship in the five patients that
were neither life-threatening nor required hospitalization. The results in the study showed a positive response to
the cognitive functions in patients, who were undergoing pharmacological treatment with respect to the evaluation
(p < 0.05) before the intervention which could be interpreted as an effect of the neuroprotective properties of these
molecules.
Keywords:
Parkinson disease, erythropoietin, clinical trial, safety, NeuroEPO.
Ivonne Pedroso Ibañez, J Alzheimers Dis Parkinsonism 2019, Volume 09